Safety and Tolerability Study of AZD2171 in combination with AZD0530 in Patients with advanced solid tumours

Study identifier:D8480C00014

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Phase I, Open-Label Study To Assess the Safety, Tolerability and Pharmacokinetics of Daily Oral Doses of cediranib (RECENTIN™;AZD2171) (20, 30 or 45mg) When Co-Administered With Daily Oral Doses of AZD0530 (125mg or 175mg) in Patients with Advanced Solid Tumours

Medical condition

Neoplasms

Phase

Phase 1

Healthy volunteers

Study drug

AZD2171, AZD0530

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 May 2007

Primary Completion Date: 01 Oct 2008

Study Completion Date: 01 Oct 2009

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Essen, Ruhr, Germany

Location

Research Site

Freiburg, Baden-Wurttemberg, Germany

Location

Research Site

Herne, Ruhr, Germany

Arms	Assigned Interventions
Experimental: 1 AZD2171 Monotherapy	Drug: AZD2171 oral tablet multiple ascending doses 20, 30 or 45 mg Other Name: cediranib Other Name: RECENTIN™
Experimental: 2 AZD2171 + AZD0530	Drug: AZD2171 oral tablet multiple ascending doses 20, 30 or 45 mg Other Name: cediranib Other Name: RECENTIN™ Drug: AZD0530 oral tablet multiple ascending doses 125 mg or 175 mg

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=623&filename=CSR-D8480C00014.pdf
Download
CSR-D8480C00014.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study

information.center@astrazeneca.com

Investigators

Principal Investigator

Jane Roberston

AstraZeneca

Safety and Tolerability Study of AZD2171 in combination with AZD0530 in Patients with advanced solid tumours

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Research Site

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=623&filename=CSR-D8480C00014.pdf

CSR-D8480C00014.pdf

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator